Ohio State University www.osu.edu through their Ohio State Innovation Foundation, and Nationwide Children’s Hospital www.nationwidechildrens.org is partnering with ENTvantage Diagnostics Inc. www.entvantagedx.com, to license a technology capable of rapidly diagnosing bacterial sinusitis. ENTvantage develops and markets rapid in-office diagnostic tests to provide primary care and ENT physicians with timely information on the causes of ear, nose, and throat illnesses.
Determining the primary cause of sinusitis remains a clinical challenge for physicians. Different kinds of medication are often given to a patient until a specific medication is found that proves to be effective in improving the sinusitis condition.
“The lack of diagnostic tools has led physicians to over prescribe antibiotics to treat sinusitis when they are not needed. We know that we can provide physicians with timely information to better diagnose the underlying cause of these illnesses that will lead to better management of sinusitis,” said Joe Skraba, President and CEO of ENTvantage.
The jointly-created technology which is a class two medical device will enable the company to develop a diagnostic kit to cost $15 based on the technology so that physicians will be better equipped with information when making a bacterial sinusitis diagnosis.
The diagnostic kit will enable physicians to take a sample swab from a patient’s nose, perform a rapid analysis, and have the results the next day. In the future, there are plans to commercialize the diagnostic test kit to physicians worldwide.
Nationwide Children’ Hospital and Ohio State have had a long–standing collaborative history and will continue to work together on several fronts to help commercialize a broad range of medical devices, pharmaceuticals, and biotech products.